Surgical Adhesions Prevention Data Presented at AAGL
ARC Medical Inc. has released new findings that shed light on the prevention of Surgical Adhesions in gynecologic, obstetric, and abdominal surgeries. At the 54th AAGL Global Congress held in Vancouver, the company presented GLAD-01 clinical trial outcomes for IPCOAT, its novel liquid surgical adhesion barrier. The clinical and nonclinical data collectively emphasize the device’s potential to reshape surgical recovery by reducing postoperative complications linked to internal scar formation.
The GLAD-01 trial, conducted with 76 healthy volunteers, confirmed that IPCOAT is safe, well tolerated, and accepted at doses up to 3 mL/kg, with or without enoxaparin sodium. The Independent Data and Safety Monitoring Committee, along with ARC’s Clinical Steering Committee, has recommended a dose range of 2 to 3 mL/kg for future surgical evaluations. These results provide a strong foundation for upcoming clinical research in gynecologic endometriosis surgery patients.
Surgical Adhesions Research Strengthens Clinical Understanding
The nonclinical safety and efficacy studies also reinforced IPCOAT’s capability to prevent Surgical Adhesions across the entire abdominopelvic cavity. Unlike conventional films or gels that only protect limited tissue surfaces, IPCOAT functions as a flowing liquid barrier. Once applied, it moves throughout the surgical cavity and creates a temporary physical separation between tissues, reducing the risk of adhesion formation.
Head-to-head comparisons presented at AAGL highlighted that IPCOAT provides broader coverage than standard gel-based or film-based adhesion barriers, which often fail to reach deeper or wider areas within the abdomen. This expanded reach is significant because Surgical Adhesions remain the most common postoperative complication, contributing to infertility, chronic pelvic pain, bowel obstruction, and challenging reoperations.
Clinical Insights Highlight Growing Need for Adhesion Prevention
Clinical leaders at ARC emphasized that surgical adhesions form in more than 31% of patients after gynecologic, obstetric, or abdominal surgery. Despite advanced surgical techniques, effective adhesion-prevention tools are still limited. IPCOAT’s ease of use in both open and minimally invasive procedures may help fill this long-standing clinical gap. By providing effective coverage throughout the abdominopelvic cavity, IPCOAT aims to reduce patient risk and support smoother recoveries.
Future of Surgical Adhesions Solutions in Women’s Health
With the completion of the GLAD-01 clinical trial and presentation of extensive nonclinical data, ARC Medical is now moving into the next phase of research. A new clinical trial will evaluate IPCOAT in gynecologic endometriosis surgery patients at a dose of 2 mL/kg. As the need for improved adhesion prevention solutions grows, ARC’s commitment to advancing women’s health positions IPCOAT as a promising candidate for future surgical standards.
